---
title: "Roivant Q1 FY27 net loss widens to $290.61 million; revenue slips to $1.44 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295095744.md"
description: "Roivant Sciences reported a Q1 FY27 GAAP net loss of $290.61 million, widening from the prior year, while revenue slipped to $1.44 million. R&D and G&A expenses increased significantly, with G&A rising due to personnel costs linked to the Moderna settlement. Non-GAAP net loss also widened to $243.69 million. The company holds $3.9 billion in cash and targets a brepocitinib launch in dermatomyositis by late September 2026."
datetime: "2026-08-06T11:07:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295095744.md)
  - [en](https://longbridge.com/en/news/295095744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295095744.md)
generator: "portal-rs"
---

# Roivant Q1 FY27 net loss widens to $290.61 million; revenue slips to $1.44 million

-   Roivant posted a GAAP net loss of USD 290.61 million, widening from USD 273.91 million a year earlier; GAAP loss per share improved to USD 0.26 from USD 0.33. \* GAAP revenue slipped to USD 1.44 million from USD 2.17 million; GAAP R&D expense rose to USD 202.02 million from USD 152.92 million. \* GAAP G&A expense increased to USD 165.53 million from USD 134.02 million, largely on higher personnel costs tied to the Moderna settlement. \* Non-GAAP net loss widened to USD 243.69 million from USD 170.12 million; non-GAAP R&D climbed to USD 192.95 million from USD 141.03 million. \* Cash, cash equivalents, restricted cash and marketable securities totaled USD 3.9 billion; brepocitinib launch in dermatomyositis targeted by end-September 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 million](https://longbridge.com/en/news/296660931.md)
- [Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares](https://longbridge.com/en/news/296284164.md)
- [Aptorum Group GAAP EPS of -$1.60](https://longbridge.com/en/news/296654186.md)
- [XORTX Therapeutics Inc. GAAP EPS of -$1.05](https://longbridge.com/en/news/296650983.md)
- [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**